Nalin Choudhary1, Kenneth Tan2,3,4, Atul Malhotra5,6,7. 1. Monash University, Melbourne, Australia. 2. Monash Newborn, Monash Children's Hospital, Melbourne, Australia. 3. The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia. 4. Department of Paediatrics, Monash University, Melbourne, Australia. 5. Monash Newborn, Monash Children's Hospital, Melbourne, Australia. atul.malhotra@monash.edu. 6. The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia. atul.malhotra@monash.edu. 7. Department of Paediatrics, Monash University, Melbourne, Australia. atul.malhotra@monash.edu.
Abstract
Neonatal units have started to switch from using conventional soy-based to alternate lipid emulsions, like SMOFlipid. SMOFlipid has been associated with an improvement in biochemical parameters and delays progression of parenteral nutrition-associated liver disease (PNALD). This retrospective epoch study aimed to compare clinically relevant neonatal outcomes in preterm infants (< 32 weeks), receiving SMOFlipid versus Intralipid. We compared clinical outcomes in two epochs-epoch 1 (Intralipid, October 2013-June 2015) versus epoch 2 (SMOFlipid, July 2015-March 2017). Primary outcome studied was mortality and rates of severe neonatal morbidities. Univariate and multivariate regression was conducted to determine risk for mortality and PNALD. A total of 222 infants (epoch 1, 123 versus epoch 2, 99) were included in the study. A higher incidence of late onset sepsis (56 versus 30%, p < 0.005) was observed in epoch 1. There was no significant difference in mortality or rates of any other severe neonatal morbidity. The type of lipid emulsion did not have a significant effect on mortality or PNALD on regression analysis. CONCLUSION: Use of SMOFlipid as the primary lipid emulsion seems to have minimal effect on rates of clinically important neonatal outcomes; however, long-term effects need to be further evaluated. What is Known: • Many neonatal units have started replacing traditional soy-based lipid formulations with SMOFlipid (ω-3 enriched lipid emulsion), as the primary lipid component in parenteral nutrition for preterm infants. • While there is evidence associating improved liver function and balanced essential fatty acid levels in infants receiving SMOFlipid, there is a lack of evidence evaluating relevant clinical outcomes in infants receiving SMOFlipid versus traditional lipid formulations. What is New: • The influence of SMOFlipid on a series of clinical outcomes in an at-risk preterm population is presented. • SMOFlipid appears to be well tolerated in preterm infants with minimal side effects, and some growth benefits seen.
Neonatal units have started to switch from using conventional soy-based to alternate lipid emulsions, like SMOFlipid. SMOFlipid has been associated with an improvement in biochemical parameters and delays progression of parenteral nutrition-associated liver disease (PNALD). This retrospective epoch study aimed to compare clinically relevant neonatal outcomes in preterm infants (< 32 weeks), receiving SMOFlipid versus Intralipid. We compared clinical outcomes in two epochs-epoch 1 (Intralipid, October 2013-June 2015) versus epoch 2 (SMOFlipid, July 2015-March 2017). Primary outcome studied was mortality and rates of severe neonatal morbidities. Univariate and multivariate regression was conducted to determine risk for mortality and PNALD. A total of 222 infants (epoch 1, 123 versus epoch 2, 99) were included in the study. A higher incidence of late onset sepsis (56 versus 30%, p < 0.005) was observed in epoch 1. There was no significant difference in mortality or rates of any other severe neonatal morbidity. The type of lipid emulsion did not have a significant effect on mortality or PNALD on regression analysis. CONCLUSION: Use of SMOFlipid as the primary lipid emulsion seems to have minimal effect on rates of clinically important neonatal outcomes; however, long-term effects need to be further evaluated. What is Known: • Many neonatal units have started replacing traditional soy-based lipid formulations with SMOFlipid (ω-3 enriched lipid emulsion), as the primary lipid component in parenteral nutrition for preterm infants. • While there is evidence associating improved liver function and balanced essential fatty acid levels in infants receiving SMOFlipid, there is a lack of evidence evaluating relevant clinical outcomes in infants receiving SMOFlipid versus traditional lipid formulations. What is New: • The influence of SMOFlipid on a series of clinical outcomes in an at-risk preterm population is presented. • SMOFlipid appears to be well tolerated in preterm infants with minimal side effects, and some growth benefits seen.
Authors: Rafeeq Muhammed; Ronald Bremner; Sue Protheroe; Tracey Johnson; Chris Holden; M Stephen Murphy Journal: J Pediatr Gastroenterol Nutr Date: 2012-06 Impact factor: 2.839
Authors: Hester Vlaardingerbroek; Marijn J Vermeulen; Virgilio P Carnielli; Frédéric M Vaz; Chris H P van den Akker; Johannes B van Goudoever Journal: J Pediatr Gastroenterol Nutr Date: 2014-04 Impact factor: 2.839
Authors: Iva Hojsak; Virginie Colomb; Christian Braegger; Jiri Bronsky; Cristina Campoy; Magnus Domellöf; Nicholas Embleton; Nataša Fidler Mis; Jessie M Hulst; Flavia Indrio; Alexandre Lapillonne; Walter Mihatsch; Christian Molgaard; Johannes van Goudoever; Mary Fewtrell Journal: J Pediatr Gastroenterol Nutr Date: 2016-05 Impact factor: 2.839
Authors: Xue Fan; Ying Tang; Jun Tang; Juan Chen; Jing Shi; Hua Wang; Bin Xia; Yi Qu; Dezhi Mu Journal: J Perinatol Date: 2020-07-07 Impact factor: 2.521
Authors: Meredith A Baker; Bennet S Cho; Lorenzo Anez-Bustillos; Duy T Dao; Amy Pan; Alison A O'Loughlin; Zachary M Lans; Paul D Mitchell; Vania Nosé; Kathleen M Gura; Mark Puder; Gillian L Fell Journal: Am J Clin Nutr Date: 2019-04-01 Impact factor: 7.045
Authors: Stephen L Harvey; Brian P Fallon; Jennifer S McLeod; Niki Matusko; Raja Rabah; Meghan A Arnold; Alvaro Rojas-Pena; Robert H Bartlett; George B Mychaliska Journal: ASAIO J Date: 2022-04-05 Impact factor: 3.826